Patents by Inventor KIMBERLY LUMSDEN

KIMBERLY LUMSDEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160194381
    Abstract: Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject having a retinoid-responsive condition. Retinoid-responsive conditions illustratively include acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma.
    Type: Application
    Filed: March 22, 2016
    Publication date: July 7, 2016
    Inventors: Diane Thiboutot, Amanda Nelson, Kimberly Lumsden
  • Patent number: 9308239
    Abstract: Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject having a retinoid-responsive condition. Retinoid-responsive conditions illustratively include acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma.
    Type: Grant
    Filed: February 26, 2009
    Date of Patent: April 12, 2016
    Assignee: The Penn State Research Foundation
    Inventors: Diane Thiboutot, Amanda Nelson, Kimberly Lumsden
  • Publication number: 20090311213
    Abstract: Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (NGAL), an NGAL analog, an NGAL stimulator and an analog of an NGAL stimulator, to a subject having a retinoid-responsive condition. Retinoid-responsive conditions illustratively include acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma.
    Type: Application
    Filed: February 26, 2009
    Publication date: December 17, 2009
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: DIANE THIBOUTOT, AMANDA NELSON, KIMBERLY LUMSDEN